Findings of Cancer Patients

Cancer Pharma Firm Rankings

Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) — The “The Corporate Reputation of Pharma in 2021 – The Patient Perspective – Cancer Version – The Views of 520 Cancer Patient Groups” report has been added to ResearchAndMarkets.com’s providing.

The ‘Corporate Reputation of Pharma’ survey – most cancers version, now in its ninth yr, and two years into the Covid-19 pandemic.

Between November 2021-February 2022, the survey collected the opinions of 520 most cancers affected person teams on the efficiency of the pharmaceutical business throughout 2021.

Patient teams responding to the ‘Corporate Reputation of Pharma’ survey are uniquely positioned to touch upon the pharma business’s efficiency throughout the pandemic. Patient teams not solely perceive the perceptions of sufferers, however are additionally the one healthcare stakeholder to community with all different stakeholders within the healthcare system.

FINDINGS AT INDUSTRY LEVEL

The 520 most cancers affected person teams responding to the 2021 ‘Corporate Reputation’ survey rated the pharma business extra favourably for company status than their predecessors in all earlier years. 67% of 2021’s respondent most cancers affected person teams acknowledged that the business had an “Glorious” or “Good” company status, towards 57% saying the identical in 2020.

Though many sufferers with most cancers suffered from the oblique penalties of the pandemic, the sentiment of most cancers affected person teams in direction of business, and to its achievements-particularly in relation to the Covid-19 pandemic-remained optimistic throughout 2020 and 2021. 81% of 2021’s 520 respondent most cancers affected person teams thought the pharma business “Very efficient” or “Efficient” at supporting sufferers throughout the Covid-19 pandemic-higher than the equal figures acquired from 2021’s respondent affected person teams of different remedy areas.

Nonetheless, 2021’s respondent most cancers affected person teams should not uniform of their views in regards to the pharma business’s status. Lung-cancer affected person teams had been essentially the most optimistic in regards to the pharma business in 2021; blood, digestive, and rare-cancer affected person teams had been the least optimistic. So, why the distinction?

Story continues

Cancer affected person teams which marked pharma down for its status in 2021 pointed to many unmet areas of affected person want in most cancers R&D, together with:

• Patient entry to most cancers medicines.

• The want to emphasize the standard of lifetime of sufferers with most cancers.

• The want for real-world proof (RWE) on the tolerability and unwanted effects of most cancers medicines.

• The want for most cancers R&D to think about bigger affected person populations.

The report offers highlights on:

• How the analyst measures pharma’s company status from a affected person perspective;

• The headline outcomes of the 2021 survey, from the attitude of most cancers affected person teams;

• The firms included within the 2021 most cancers evaluation; and

• The profiles of 2021’s respondent most cancers affected person teams.

Firm Rankings

• The top-three pharma firms out of 30 firms, ranked for his or her total company status in 2021, assessed by respondent most cancers affected person teams accustomed to the corporate: Pfizer, 1st – Roche/Genentech, 2nd – Novartis, third.

• The top-three pharma firms out of 26 firms, ranked for his or her total company status in 2021, assessed by respondent most cancers affected person teams working with the corporate: Pfizer, 1st – Roche/Genentech, 2nd – Janssen, third.

Who Ought to Learn this Report?

Buyer Varieties (Organisations)

• Pharma firms

• Biopharma firms

  • Regulatory authorities (e.g EMA, FDA)

  • NGOs and well being charities (often FOC) together with Patient Groups

  • Analysis and academia

Job Titles/Features for Pharma and Biopharma Organisations

Core:

• Patient Relations

• Corporate Reputation

• Public Affairs

• Skilled Affairs

• Patient Advocacy

• Communications

• Market Analysis

Secondary:

• R&D

• Well being economics

• Outcomes Analysis

• Medical Affairs

• Advertising

• Model groups

• Market Entry

• Regulatory

Key Matters Lined:

• Government abstract

• Cancer patient-group relationships with pharma, 2021

• Trade-wide findings, 2021

• Rankings of 30 pharma firms, 2021 v. 2020, as assessed by respondent most cancers affected person teams accustomed to the businesses

• Rankings of 26 pharma firms, 2021 v. 2020, as assessed by respondent most cancers affected person teams working with the businesses

• Rankings of 13 ‘big-pharma’ firms, 2021 v. 2020, as assessed by respondent most cancers affected person teams accustomed to the businesses

• Rankings of 13 ‘big-pharma’ firms, 2021 v. 2020, as assessed by respondent most cancers affected person teams working with the businesses

• Rankings of 5 generic pharma firms, 2021 v. 2020, as assessed by respondent most cancers affected person teams accustomed to the businesses

• Profiles of the 30 firms, 2021 (v. 2020)

Appendices

• Profiles of respondent most cancers affected person teams, 2021

• Record of respondent most cancers affected person teams that wished to be attributed, 2021

• Commentaries and suggestions from respondent most cancers affected person teams on how pharma can enhance, 2021-2022

• The views of 84 blood-cancer affected person teams Complement

• The views of 92 breast- and ladies’s-cancer affected person teams Complement

• The views of 28 lung-cancer affected person teams Complement

• The views of 42 prostate- and males’s-cancer affected person teams Complement

Profiles of the 30 firms, 2021

• AbbVie

• Amgen

• Astellas Pharma

• AstraZeneca

• Bayer

• Boehringer Ingelheim

• Bristol Myers Squibb

• Daiichi Sankyo

• Dr Reddy’s

• Eisai

• Eli Lilly

• Gilead Sciences

• GSK

• Ipsen

• Janssen

• Menarini

• Merck & Co/MSD

• Merck KGaA/EMD Serono

• Mylan

• Novartis

• Otsuka

• Pfizer

• Pierre Fabre

• Roche/Genentech

• Sandoz

• Sanofi

• Servier

• Solar Pharma

• Takeda

• Teva

For extra details about this report go to https://www.researchandmarkets.com/r/4ckl6f

Attachments

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wooden,Senior Press Supervisor press@researchandmarkets.com For E.S.T Workplace Hours Name 1-917-300-0470 For U.S./ CAN Toll Free Name 1-800-526-8630 For GMT Workplace Hours Name +353-1-416-8900